Janus kinase inhibitor - Open Access .click

Results 221 to 230 of about 51,155 (263)

Some of the next articles are maybe not open access.

Rheumatology Quarterly
With a better understanding of the pathogenesis of inflammatory rheumatic diseases, different treatments pathways have emerged. In recent years, Janus kinase inhibitors (JAKinibs) have become one of these treatment pathways. It has come into clinical use as an effective treatment agent, especially in rheumatoid arthritis and spondyloarthropathy. In the
openaire +1 more source

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

Journal of the American Academy of Dermatology, 2023
, Joseph F Fowler
exaly

Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Journal of the American Academy of Dermatology, 2022
Maria Colavincenzo +2 more
exaly

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study

Journal of the American Academy of Dermatology, 2022
John W Frew
exaly

Janus kinase inhibitors

Reactions Weekly
+4 more sources

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

Journal of the American Academy of Dermatology, 2015
Brett KING
exaly

Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology

Current Medicinal Chemistry, 2017
Romana Čeović, Krešimir Kostovic
exaly